Cwm LLC Grows Stock Position in BridgeBio Pharma, Inc. $BBIO

Cwm LLC increased its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 29.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,830 shares of the company’s stock after purchasing an additional 1,569 shares during the quarter. Cwm LLC’s holdings in BridgeBio Pharma were worth $295,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of BBIO. Cambridge Investment Research Advisors Inc. lifted its stake in shares of BridgeBio Pharma by 29.4% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 30,802 shares of the company’s stock worth $1,065,000 after acquiring an additional 6,997 shares during the period. GAMMA Investing LLC raised its holdings in BridgeBio Pharma by 71.0% during the first quarter. GAMMA Investing LLC now owns 920 shares of the company’s stock worth $32,000 after purchasing an additional 382 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in BridgeBio Pharma in the first quarter valued at about $251,000. Moss Adams Wealth Advisors LLC boosted its holdings in BridgeBio Pharma by 49.2% in the 2nd quarter. Moss Adams Wealth Advisors LLC now owns 24,172 shares of the company’s stock valued at $1,044,000 after purchasing an additional 7,970 shares in the last quarter. Finally, Baird Financial Group Inc. acquired a new position in BridgeBio Pharma during the 1st quarter worth approximately $1,429,000. 99.85% of the stock is owned by institutional investors and hedge funds.

BridgeBio Pharma Stock Up 0.8%

NASDAQ:BBIO opened at $54.26 on Monday. BridgeBio Pharma, Inc. has a 52-week low of $21.72 and a 52-week high of $57.49. The stock has a fifty day simple moving average of $52.42 and a 200-day simple moving average of $44.55. The company has a market capitalization of $10.37 billion, a PE ratio of -13.27 and a beta of 1.36.

BridgeBio Pharma (NASDAQ:BBIO) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.12). The company had revenue of $110.57 million for the quarter, compared to analysts’ expectations of $98.46 million. The company’s revenue was up 4999.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.39) earnings per share. As a group, equities analysts anticipate that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Thomas Trimarchi sold 42,237 shares of the firm’s stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $49.48, for a total transaction of $2,089,886.76. Following the completion of the transaction, the chief financial officer directly owned 421,081 shares of the company’s stock, valued at $20,835,087.88. This trade represents a 9.12% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Maricel Apuli sold 1,000 shares of BridgeBio Pharma stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $45.44, for a total value of $45,440.00. Following the transaction, the chief accounting officer owned 141,859 shares of the company’s stock, valued at $6,446,072.96. This represents a 0.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 597,913 shares of company stock valued at $29,034,227. Corporate insiders own 18.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on BBIO shares. Cantor Fitzgerald restated an “overweight” rating and issued a $95.00 price target on shares of BridgeBio Pharma in a research note on Tuesday, July 29th. Truist Financial assumed coverage on shares of BridgeBio Pharma in a research report on Monday, July 21st. They set a “buy” rating and a $66.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $70.00 price target on shares of BridgeBio Pharma in a report on Monday, September 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BridgeBio Pharma in a research note on Friday. Finally, Scotiabank boosted their price objective on shares of BridgeBio Pharma from $55.00 to $57.00 and gave the stock a “sector outperform” rating in a report on Wednesday, August 6th. Sixteen analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $65.25.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.